VCYT — VERACYTE, INC.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1384101 ·
Last close
$41.47
Market Cap
$3.33B
52W High
$60.91
52W Low
$40.10
ADV30
1,304,298
Next earnings
2026-07-30
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026
Mar 2026 139,071,000 101,159,000 22,646,000 28,707,000 1,436,400,000 263,136,000 91,994,000
Dec 2025 140,636,000 101,973,000 39,908,000 41,149,000 1,406,019,000 362,578,000 96,443,000
Sep 2025 131,872,000 91,282,000 23,112,000 19,137,000 1,367,787,000 315,573,000 110,120,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$166,160,000
Investing CF
$-85,352,000
Financing CF
$-4,367,000
CapEx
$-10,820,000
Dividends Paid
Buybacks
EPS Diluted TTM
$1.41
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-348,923,000
Inventory
$21,416,000
Receivables
$50,112,000
ST Investments
$175,924,000
EBIT TTM
$90,747,000
Pretax Income TTM
$90,747,000
Interest Exp TTM
$0
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$561,900,032
EBITDA
$113,515,000
Free Cash Flow
$106,230,872
Enterprise Value
$2,956,206,848
Total Cash
$485,232,000
Total Debt
$40,107,000
Shares Out
80,390,731
Trailing EPS
$1.40
Book Value
$17.28
ROE
8.8%
ROA
4.1%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 517,145,000 78,282,000 66,353,000 1,406,019,000 96,443,000 136,307,000
Dec 2024 445,764,000 19,510,000 24,138,000 1,300,035,000 124,069,000 75,096,000
Dec 2023 361,051,000 -17,446,000 -74,404,000 1,114,906,000 70,804,000 44,222,000
Dec 2022 296,536,000 -35,340,000 -36,560,000 1,156,422,000 81,222,000 7,535,000

TTM Snapshot

Revenues TTM
$341,930,000
NetIncome TTM
$-37,315,000
OpCashFlow TTM
$0
Assets (Latest)
$1,300,035,000
Forward EPS
$1.95

Max Pain — expiry 2026-12-18

max pain strike: $35.00 · spot: $41.47 · call oi: 2,651 · put oi: 97
Expected Move to 2026-12-18: ±$10.72 (25.86%) — implied range $30.75$52.20 · ATM straddle on $40.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
GRAL GRAIL, Inc. $3.42B $76.58
OPCH Option Care Health, Inc. $3.55B $23.67
NHC NATIONAL HEALTHCARE CORP $3.58B $228.38
AVAH Aveanna Healthcare Holdings, Inc. $2.99B $13.70
BKD Brookdale Senior Living Inc. $2.89B $12.12

News headlines (Yahoo Finance, 1h cache)

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?
2026-07-31 10:06 · Yahoo
Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...
2026-07-31 05:03 · Yahoo
Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat
2026-07-30 13:17 · Yahoo
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
2026-07-23 14:00 · Yahoo
Reasons to Retain Doximity Stock in Your Portfolio for Now
2026-08-24 18:47 · Yahoo
Reasons to Retain Cardinal Health Stock in Your Portfolio for Now
2026-08-24 18:47 · Yahoo
AMN Stock Rallies Nearly 119% YTD: What's Behind the Momentum?
2026-08-24 18:23 · Yahoo
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
2026-08-24 15:15 · Yahoo
Is it the Right Time to Retain DGX Stock in Your Portfolio?
2026-08-21 15:43 · Yahoo
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
2026-08-21 13:54 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.